Evidence map›Paper›PMID 28695388›Full record

ArticleAIDS and behavior2018

Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users.

Roman Shrestha, Pramila Karki, Frederick L Altice, Oleksandr Dubov, Liana Fraenkel, Tania Huedo-Medina, Michael Copenhaver

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03282890 (Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs), which is not on this map. Cited by 35 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 4 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03282890 nacompletednot on this map

Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs

TypeinterventionalSponsorUniversity of ConnecticutRan2017 to 2023Enrolled237ConditionsRisk Behavior, HIV/AIDS, Medication Adherence, Substance AbuseArmsCHRP-BB
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Roman ShresthaDepartment of Community Medicine & Health Care, University of Connecticut Health Center, 263 Farmington Avenue, MC 6325, Farmington, CT, 06030-6325, USA. Roman.Shrestha@UConn.edu.ORCID 0000-0003-4340-3101
Pramila KarkiInstitute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
Frederick L AlticeInstitute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
Oleksandr DubovSchool of Public Health, Loma Linda University, Loma Linda, CA, USA.
Liana FraenkelDepartment of Internal Medicine, Section of Rheumatology, School of Medicine, Yale University, New Haven, CT, USA.
Tania Huedo-MedinaInstitute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
Michael CopenhaverInstitute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
University of Connecticut · USLoma Linda University · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaR01DA025943 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2008 to 2012
$2.7M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Improving Decision Making in Patients with Rheumatic DiseaseK24AR060231 · NIAMS · YALE UNIVERSITY · PI FRAENKEL, LIANA · 2011 to 2018
$1.2M
HIV Prevention and Adherence Among Priority Drug Using PopulationsK02DA033139 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI COPENHAVER, MICHAEL · 2013 to 2017
$697k
NCATS NIH HHS UL1 TR001863NIAMS NIH HHS K24 AR060231NIDA NIH HHS K02 DA033139NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA025943
6 · The paper itself

Abstract

Although people who use drugs (PWUD) are one of the key risk populations who could benefit from the use of pre-exposure prophylaxis (PrEP), to date, little attention has been given to incorporating PrEP into HIV prevention approaches targeting this underserved group. This study investigated the acceptability of PrEP based on a number of known PrEP attributes among high-risk PWUD in a drug treatment setting. A total of 400 HIV-negative PWUD, who reported drug- and/or sex-related risk behaviors were recruited from a methadone clinic to complete a stated preference (full-profile conjoint) survey. Participants ranked the eight hypothetical PrEP program scenarios with varied combinations of six attributes related to PrEP (cost, dosing, efficacy, side-effects, treatment setting, and frequency of HIV testing). SPSS conjoint procedure was used to estimate the relative importance of each attribute and preferences across eight possible PrEP delivery programs. PrEP acceptability ranged from 30.6 to 86.3% with a mean acceptability of 56.2% across the eight hypothetical PrEP program scenarios. The PrEP program scenario with the highest acceptability had the following attribute levels: insurance covered, daily dosing, 95% effective, no side-effects, treatment at HIV clinic, and HIV testing needed every 6 months. The cost associated with PrEP was the most important attribute (relative importance score: RIS = 38.8), followed by efficacy (RIS = 20.5) and side effects (RIS = 11.9); other attributes had no significant effect. Our findings reported a high acceptability of PrEP in response to different PrEP program scenarios with different attribute profiles. As the result of having this information, researchers and policymakers will be better equipped for evidence informed targeting and dissemination efforts to optimize PrEP uptake among this underserved population.

Indexed as

Patient PreferenceAdultAgedAmbulatory Care FacilitiesConnecticutCross-Sectional StudiesDrug UsersFemaleHIV InfectionsHomosexuality, MaleHumansMaleMethadoneMiddle AgedPatient Acceptance of Health CarePre-Exposure ProphylaxisMethadoneConjoint analysisHIV preventionImplementation sciencePatient preferencesPeople who use drugs (PWUD)Pre-exposure prophylaxis (PrEP)

Identifiers

PMID28695388
PMCPMC5762432
OpenAlexW2735419956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.